The transplantation of a large number of stem cells can overcome graft rejection but with the increased risk of GVHD. In this study, we analyzed the outcome of 32 adult patients with acquired severe aplastic anemia (SAA) who were at a high risk for graft rejection, including multiple transfusions (median 147 units, range 20-680) and long disease duration (median 67 months, range 3-347), and who had received both BM and CD34 þ -purified PBSCs from an HLA-matched sibling donor to reduce graft rejection. T cells in PBSCs were depleted using a magnetic-activated cell sorting method (CliniMACS system). Conditioning regimens consisted largely of CY and antithymocyte globulin (ATG) with fludarabine (FLU) or procarbazine (PCB). With a median follow-up of 89 months, the 8-year probability of survival was 87.5%. Neutrophils and plts promptly recovered, and none of the patients developed graft failure. The cumulative incidences of acute and chronic GVHD were 9.4 and 18.0%, respectively. Sustained engraftment and excellent survival without an apparent increase in the rate of GVHD in high-risk patients using the current approach showed that high-dose SCT with both BM and CD34 þ -purified PBSCs may yield better outcomes in heavily transfused and/or allo-immunized patients with SAA.
Introduction
Allogeneic hematopoietic SCT (HSCT) from an HLAmatched sibling is a curative therapy in the majority of acquired severe aplastic anemia (SAA), 1, 2 and the most recent cohort that reported to the International Bone Marrow Transplant Registry showed a 5-year survival rate of 77%. 3 A recent prospective randomized study of allogeneic HSCT from an HLA-matched sibling donor suggested that better outcome with HSCT over time relates to advances in supportive care. 4 However, GVHD remains a serious problem for older patients, in whom GVHD incidence was reported as 20-30% for grade II-IV acute GVHD, and 30-40% for chronic GVHD. 3, 5, 6 On the other hand, graft rejection is currently infrequent, which is probably a benefit of less immunogenic blood products (leukocyte-depleted transfusion) from fewer donors (use of single-donor plts). 7, 8 However, graft rejection remains a problem for 5-15% of patients, in particular, heavily transfused patients, 4, [9] [10] [11] and graft rejection was the sole factor associated with long-term survival in our previous report. 1 Various methods using large doses of stem cells and/or more intense conditioning regimens have been developed in an effort to overcome graft rejection. 4, [12] [13] [14] A retrospective study, in which G-CSF-mobilized PBSCs were compared with BM as a source of stem cells for HSCT, showed no reductions in graft rejection, more chronic GVHD and worse outcomes with the use of PBSCs in younger patients. 12 A recent randomized controlled study of conditioning regimens has revealed that the addition of antithymocyte globulin (ATG) to CY resulted in no significant improvements in the outcomes, particularly with regard to graft rejection and GVHD. 4 A new trial assessing the addition of fludarabine (FLU) to a reduced dose of CY with ATG has shown good engraftment in heavily sensitized patients, whereas a high incidence of acute and chronic GVHD was also noted in that study. 13 On the basis of feasibility studies conducted by other groups, 15, 16 we have applied a method that uses the combination of unmanipulated BM and T-cell-depleted PBSCs as a source of stem cells for high-risk patients with SAA to ensure engraftment. Our pilot studies showed a reduction in graft rejection and a faster engraftment speed, without any apparent increase in GVHD. 14, 17 This study describes the long-term transplant outcome using a combination of unmanipulated BM and T-cell-depleted PBSCs through a magnetic-activated cell sorting method in high-risk adult patients with SAA to decrease graft rejection without an increase in GVHD.
Patients and methods

Patient selection
Between December 1999 and May 2007, 32 consecutive adult patients with SAA at an increased risk of graft rejection, including 7 patients in our previous study, 17 underwent allogeneic HSCT from HLA-matched sibling donors at the Catholic Blood and Marrow Transplantation Center in Korea, with the patients' fully informed consent. We adopted the minimal criteria for high risk of graft rejection, as we previously reported, 14, 17 which included history of multiple transfusion (more than 40 units of RBC ± plts) and/or a period of 3 years or longer before transplant. During the same period of time, 73 patients with SAA underwent allogeneic HSCT from HLA-matched sibling donors with BM (n ¼ 70) or PBSCs (n ¼ 3) as a source of stem cells. SAA was defined in accordance with the criteria of the International Aplastic Anemia Study Group. 18 Transplant characteristics A total of 19 patients received a combination of CY (200 mg/kg i.v.), ATG (3.75 mg/kg i.v., rabbit type, Pasteur Merieux, Lyon, France) and PCB, 37.5 mg/kg p.o. After we experienced a death as the result of congestive heart failure induced by CY conditioning, 17 the combination of a reduced dose of CY (100 mg/kg i.v.), ATG (10 mg/kg i.v., rabbit type, IMTIX-Sangstat, Lyon, France) and FLU, 180 mg/m 2 i.v. was used as a new preparative regimen for 10 patients since 2002. Three other patients with a history of graft rejection to previous HSCT received irradiation-based conditioning regimens (750 cGy of total nodal irradiation and ATG 3.75 mg/kg i.v.). Among the three patients, two patients had previously received BM after conditioning with CY/ATG/FLU, whereas the other patient who underwent two previous HSCTs had received BM after conditioning with CY/ATG/FLU for the first HSCT and PBSCs after conditioning with total nodal irradiation and ATG for the second HSCT. The prophylactic regimen for GVHD was a combination of CYA and short-term MTX. At 3 months after transplantation, in the absence of GVHD, a cyclosporine taper was initiated. G-CSF was administered to all patients at a dose of 5 mg/kg per day s.c. from day 7 after the transplant until neutrophil recovery. The other general transplantation procedures were performed as described in previous reports. 19, 20 Stem cell collection and CD34 þ enrichment from PBSCs To obtain high-dose stem cells, unmanipulated BM cells were infused after CD34 þ -enriched PBSC transplantation.
The process of stem cell collection was described in our previous reports. 14, 17 In brief, G-CSF (10 mg/kg/day) was administered to donors by s.c. injection and continued for 5 days. The leukaphereses were performed on days 5 and 6 of G-CSF administration. The PBSC preparations were depleted of T lymphocytes through a magnetic-activated cell sorting (CliniMACS system, Miltenyi Biotec, Bergisch Gladbach, Germany). 21 The purity and recovery of the isolated CD34
þ cells and the contamination of CD3 þ cells were evaluated using flow cytometry. BM harvesting was performed 48 h after the last leukaphereses at a volume of 15 ml per kg of recipient body weight.
Definitions
Neutrophil engraftment was defined to have occurred on the first of 3 consecutive days during which the ANC was 40.5 Â 10 9 /l. Plt engraftment was defined to have occurred on the first of 7 consecutive days with a plt count of 420 Â 10 9 /l, without transfusion support. Primary graft failure was defined as failure to achieve an ANC of 40.5 Â 10 9 /l for 3 consecutive days at any time after transplantation. Secondary graft failure was defined as the development of an ANC of o0.5 Â 10 9 /l after initial engraftment had already been achieved. Regimen-related toxicity was graded using the Bearman score. 22 GVHD was diagnosed and graded using previously published criteria. 23, 24 Statistical analysis Survival, graft failure and GVHD were the primary outcomes of interest in this study. We calculated OS from the date of transplantation until the date of death or last follow-up and the survival curves were plotted using the Kaplan-Meier method. Acute and chronic GVHD were considered as time-dependent covariates, and their incidences were calculated and plotted using cumulative incidence estimates, in which death without acute GVHD within 100 days or death without chronic GVHD were considered competing risks, respectively. 25 Statistical analyses were performed using SPSS 13.0 software (SPSS, Chicago, IL, USA) with the exception of the cumulative incidence analyses, which were carried out with R (freely distributed on the web, http://www.r-project.org/).
Results
Patients' characteristics and cell counts Patient characteristics are summarized in Table 1 . The median patient age was 39 years (range 21-52). The majority of patients (75%) had received at least one immunosuppressive agent before transplantation. The interval from the diagnosis of SAA to transplantation was prolonged (median 67 months, range, 3-347). Before transplantation, all patients had received multiple transfusions (median 147 units, range Table 2 , and these were similar to the results of our previous pilot study. 17 The mean CD34 þ cell purity after positive selection was measured as 95.8%.
Engraftment and toxicity
The donors tolerated G-CSF treatment well with only low-grade fever, bone pain and headache, which ceased after marrow harvesting. The BM harvesting procedure was rapid. In the majority of cases, it was possible for two operators to collect 1 liter of marrow during a 30-min period. The donors reported no untoward side effects after the leukaphereses and marrow harvesting. No donor received plt transfusions. All donors received autologous transfusions of RBC during marrow harvesting. Most patients experienced no significant regimen-related toxicity (grades 3 and 4). One patient who received a conditioning regimen of CY/ATG/PCB died of CY-induced myopericarditis and subsequent multiorgan failure.
GVHD and survival
Out of 32 patients, 3 had grade II-IV acute GVHD, including 2 patients with grade II and 1 patient with grade III. Two patients with grade II acute GVHD responded to methylprednisolone (2-4 mg/kg for 3-7 days) followed by rapid tapering, whereas one patient with grade III did not respond to primary treatment and died of septic conditions with refractory acute GVHD. Out of 28 evaluable patients, 5 had chronic GVHD. Three patients developed a limited type of chronic GVHD and two patients the extensive type. No deaths associated with chronic GVHD were noted in this study. The cumulative incidence of grade II-IV acute GVHD and chronic GVHD was 9.4% (95% confidence interval 3.2-27.5) and 18.0% (95% confidence interval 8.1-39.9), respectively (Figures 1a and b) . The Kaplan-Meier estimate of survival was 87.5% (95% confidence interval 76.0-99.0) with a median follow-up (Figure 1c) . Four patients died from CY-induced heart failure (n ¼ 1), acute GVHD with infection (n ¼ 1) and sepsis of unknown cause (n ¼ 2).
Discussion
In this study, all enrolled patients received multiple transfusions before HSCT, and also had features indicative of high risk for poor transplant outcome, including older age, a prolonged interval from diagnosis to HSCT and previous immunosuppressive treatment. 2 On the basis of our pilot studies, 14, 17 we used intensified conditioning regimens (CY/ATG/PCB or CY/ATG/FLU), with the exception of three patients who had a previous history of HSCT (irradiation-based regimen), and the combination of CD34 þ -purified PBSCs with unpurged BM as a stem cell source, and the long-term outcome was 87.5% of OS rate, with a median follow-up duration of 89 months (range 1-118), without both graft rejection and an apparent increase in the cumulative incidence of acute (9.4%) and chronic GVHD (18.0%).
In previous studies, high-dose blood stem cell transplants have been used, and any degree of sensitization to transplant Ag may be overcome by large doses of stem cells in PBSC grafts. 12, 26, 27 Using these approaches, graft rejection rates may be reduced, but at the cost of a substantially increased risk of chronic GVHD, which emerged as the principle cause of morbidity and mortality after HSCT and the most important risk factor for nearly long-term complications. 2, 5, 12 However, T-cell depletion to prevent GVHD resulted in very high graft failure rates after HSCT for aplastic anemia, 3 which was the reason why we added unpurged BM to T-cell-depleted PBSCs. With patients with high-risk SAA transplanted between 1995 and 1999, we showed that CD34 þ -purified PBSCs infused together with unpurged BM after an intense conditioning regimen (CY/ATG/PCB) was an effective treatment to minimize the risk of graft rejection, and to avoid increasing risks of GVHD. 14 In that study, when compared with the BM group, BM þ CD34 þ -purified PBSC group had lower graft rejection rates (7/20, 35% vs 2/20, 10%) with a comparable incidence of GVHD. Since 1999, magneticactivating cell sorting (CliniMACS system, Miltenyi Biotec), instead of an immunoadsorption biotin-avidin column (Ceprate SC, Cellpro, Bothell, WA, USA), has been used for purification of PBSCs, on the basis of our pilot study showing the superiority of magnetic cell sorting with regard to T-cell depletion and CD34 þ cell purity after positive selection. 17 Using this approach, a high dose of stem cells could be obtained without increases in the incidence of GVHD or the risk of graft failure as the result of T-cell depletion. Engineering a graft seems to minimize the disadvantages inherent in each stem cell source, which include relatively slow BM engraftment and an increased risk of chronic GVHD of PBSCs. 12, 28 Another approach to overcoming graft rejection has been to use more intense conditioning regimens targeted toward the suppression of host immunity. The optimal conditioning regimen for patients with SAA at increased risk for graft rejection is unknown. The conditioning regimen of CY þ ATG was compared with CY alone in a prospective randomized study, which revealed no differences in the rates of engraftment, GVHD and survival. 4 In our previous report, 7 of the 20 high-risk patients (35%) who received BM alone with a conditioning regimen of CY/ ATG/PCB rejected their grafts, thus showing that the intensity of conditioning regimen we used could not provide sufficient immune suppression to ensure sustained engraftment in patients at high risk for rejection. 14 Recently, Srinivasan et al. 13 showed that the sustained donor engraftment with a median follow-up of 21 months was achieved in all 26 patients who received FLU in combination with reduced doses of CY and ATG (somewhat similar to our regimen) and G-CSF-mobilized PBSCs, and suggested this approach was a feasible method to avoid graft rejection in heavily transfused patients. However, the high incidence of GVHD (65% of grade II-IV acute GVHD and 56% of chronic GVHD), which may be caused by the use of PBSCs as a source of stem cells, suggests the necessity of a more appropriate approach to reduce the incidence of GVHD. From this perspective, our approach suggests a better method of infusing sufficient amounts of stem cells to overcome graft rejection without increasing GVHD incidence.
In conclusion, overcoming graft rejection and excellent long-term survival were achieved in patients with SAA who þ -purified PBSC with BM in high-risk SAA BS Cho et al were at high risk for graft rejection, using PBSCs with T-cell depletion, infused together with unpurged BM after an intense conditioning regimen. In particular, this approach has the benefit of not apparently increasing the risk of GVHD, which is the principle cause of morbidity and mortality in HSCT for patients with SAA. High-dose HSCT with both BM and CD34 þ -purified PBSCs might be a reasonable approach for better outcomes in heavily transfused and/or allo-immunized patients with SAA. Considering the small number of patients included and retrospective nature of this study, the benefit of this approach has to be proved with prospective randomized studies.
